← Back to patent-cliff list
Palovarotene
Tier C — Watch / tradePalovarotene
Clementia Pharmaceuticals Inc
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RAR-γ
Brand：Sohonos
Indications (approved)：进行性肌肉骨化症
Regional status
US
Approved
2023-08-16
EU
Phase III
2017-11-30
China
Phase I
2021-08-19
Japan
Approved
2026-02-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Palovarotene?
Approved indications include: 进行性肌肉骨化症.
When does the Palovarotene patent expire?
No public expiry year is available for Palovarotene yet; this page updates once verified.
How do I get a quote for Palovarotene intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27